BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cyprotex (COTXF.PK) Results For The Year Ended 31 December 2009


3/17/2010 3:03:23 PM

Cyprotex PLC (AIM:CRX), the drug discovery technology and information company, today reports its final results for the year ended 31 December 2009. Cyprotex enables its customers to access secure, high quality Absorption, Distribution, Metabolism, Excretion / Toxicity (ADMET) data without incurring significant overheads. Its highly automated platform guarantees high throughput, reproducibility and rapid turnaround of ADMET data, setting new industry standards for this sector of the market.

Financial Highlights

• Revenues hit £5 million for second successive year at £5.00 million (2008: £5.18 million)

• Second year of profitability with operating profits at £0.46 million (2008: £0.57 million)

• Cash and cash equivalents up £0.49 million at £2.07 million

• Strong positive cash flow from operations at £0.90 million up £0.36 million.

Operational Highlights

• Doubled number of strategic customers in 2009 (being customers contributing annual revenues in excess of £250,000 each) from three to six

• Won over twenty new customers

• Newly internally developed assays generated over £300,000 of revenues

• Investment in laboratory space and state of the art mass spectrometer secured new strategic customer

• Strategic alliance announced with Sygnature Chemical Services Limited, a leading provider of medicinal and computational chemistry services

• Launched Cloe® Gateway, our new web based portal for access to Cyprotex services

Steve Harris, Chairman of Cyprotex PLC, said: “Cyprotex’s results represent an impressive performance against a very difficult market currently for the pre-clinical CRO sector. Cyprotex continues to attract new customers, expand its offerings and is investing in new laboratories to service both the ADME and pre-clinical toxicology markets”


Read at BioSpace.com

Cyprotex
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES